vTv Therapeutics (NASDAQ:VTVT) Raised to Buy at Zacks Investment Research

vTv Therapeutics (NASDAQ:VTVT – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday, Zacks.com reports. The brokerage presently has a $0.50 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price target would suggest a potential upside of 15.77% from the […]

Related Keywords

Blackrock ,North Carolina ,United States , ,Rafferty Asset Management ,Zacks Investment Research ,Blackrock Inc ,Samsara Biocapital ,Tv Therapeutics Inc ,Cim Investment Management Inc ,Cantor Fitzgerald ,Sigma Securities ,Translational Technology ,Get Rating ,Investment Research ,Glucokinase Activator ,High Point ,Asset Management ,Investment Management ,Two Sigma Securities ,Vtv Therapeutics ,Nasdaq Vtvt ,Vtvt ,Medical ,Upgrade ,